Bispecific Antibody CDX-527 Enters Phase 1 Trial in Solid Tumors
September 16th 2020The bispecific antibody CDX-527 is now under investigation in patients with advanced or metastatic solid tumors who have progressed during or following standard-of-care treatment with the recent initiation of a open-label phase 1 trial.
ALKS 4230 Under Exploration for Advanced Malignant Solid Tumors in ARTISTRY-3 Trial
September 15th 2020Investigators are evaluating the clinical and immunological impact of the experimental, engineered fusion protein ALKS 4230 on the tumor microenvironment of several advanced, malignant solid tumors in the recently initiated phase 2 ARTISTRY-3 trial.
Ofatumumab to Be Available Through a Patient Access Program for CLL
September 10th 2020Patients with chronic lymphocytic leukemia who are being treated with ofatumumab will soon have to get their therapy through an oncology patient access program, as Novartis will no longer be selling the drug commercially for this indication.
Daiichi Sankyo, Gustave Roussy Research Partnership Holds Promise for NSCLC, Breast Cancer Paradigms
September 8th 2020A multi-year, multi-study research collaboration between Daiichi Sankyo and Gustave Roussy Cancer Center will support the clinical, translational, and preclinical evaluation of 2 of the company’s lead antibody-drug conjugates: DS-1062 in advanced non–small cell lung cancer, and patritumab deruxtecan in metastatic breast cancer.